CBI Scene Blog

Daria Binder

Recent Posts

Inside Secrets: The Future of Abuse Deterrent Formulations

Posted by Daria Binder on Apr 30, 2015 11:10:16 AM

With increased pressure on the pharmaceutical industry to come up with creative solutions for the growing drug abuse epidemic in America and a new FDA legislation in effect, the time is now for bio/pharma manufacturers to analyze their formulations and ensure that new and existing products are meeting regulatory standards, reducing misuse potential and minimizing abuse liability. It is critical that the industry adapts quickly in order to ensure their drugs adhere to pre-marketing and post-marketing study requirements, as well as labeling mandates for improving drug safety and achieving market access.

Read More

Topics: Clinical, Compliance

Howard Doffman, VP & General Counsel at Ferring Pharmaceuticals on Social Media

Posted by Daria Binder on Aug 19, 2014 2:59:00 PM

 

Historically, the bio/pharmaceutical industry has been hesitant to adopt social media strategies, mainly due to the lack of regulatory guidance. The June 2014 FDA draft guidance on the Internet and social media has clarified some questions regarding what is considered to be appropriate messaging on social media sites, including patient/physician forums, Facebook, YouTube and Twitter (to name a few). Though the guidance is new, it has definitely helped to interpret regulatory stances on the topic.  I had the pleasure of discussing the social media draft guidance with Howard Dorfman, Vice President and General Counsel at Ferring Pharmaceuticals. He was able to shed some light on what the FDA guidance really means for industry, including how industry has and will continue to change, industry strategies, what is still unclear and what SOPs might be put in place to better utilize the social media world.

Read More

Topics: Brand & Digital Strategy, Compliance

The Full Clinical Trial Data Transparency & Limited Disclosure Debate

Posted by Daria Binder on Jan 2, 2014 10:21:00 AM

Read More

Topics: Clinical

Harry Potter’s Severus Snape & Big Pharma, a Comparison

Posted by Daria Binder on Sep 18, 2013 11:25:00 AM

Read More

Topics: Brand & Digital Strategy, Medical Affairs, Patient Access, Distribution and Channel, Compliance, Finance